Market Research Logo

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016

Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016’, provides in depth analysis on Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1)
  • The report reviews Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) Overview
Therapeutics Development
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Stage of Development
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Therapy Area
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Indication
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Companies
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Companies Involved in Therapeutics Development
Daiichi Sankyo Company, Limited
Galmed Pharmaceuticals Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Novartis AG
Sanofi
Xenon Pharmaceuticals Inc.
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Drug Profiles
Aramchol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-1940029 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-224 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SCD1 for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEN-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Dormant Projects
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Discontinued Products
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Featured News & Press Releases
Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease
Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study
Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne
Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease
Sep 24, 2015: Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial
Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America
Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States
Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production
Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers
Nov 13, 2014: Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones
Sep 23, 2014: Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH
Sep 02, 2014: Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events
Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders
Jul 08, 2014: Galmed Announces Publication of Aramchol Phase IIa Trial in the Clinical Gastroenterology and Hepatology Journal
Jun 09, 2014: Galmed Pharmaceuticals Announces the Filing of a Provisional Patent Application for the Use of Aramchol for the Treatment of Lipodystrophy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Daiichi Sankyo Company, Limited, H1 2016
Pipeline by Galmed Pharmaceuticals Ltd., H1 2016
Pipeline by GlaxoSmithKline Plc, H1 2016
Pipeline by Johnson & Johnson, H1 2016
Pipeline by Novartis AG, H1 2016
Pipeline by Sanofi, H1 2016
Pipeline by Xenon Pharmaceuticals Inc., H1 2016
Dormant Projects, H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report